Navarrete, Felipe A.
Alvau, Antonio
Lee, Hoi Chang
Levin, Lonny R.
Buck, Jochen
Leon, Patricia Martin-De
Santi, Celia M.
Krapf, Dario
Mager, Jesse
Fissore, Rafael A.
Salicioni, Ana M.
Darszon, Alberto
Visconti, Pablo E.
Article History
Received: 20 May 2016
Accepted: 31 August 2016
First Online: 15 September 2016
Competing interests
: Drs Levin and Buck report owning equity interest in CEP Biotech which has licensed commercialization of a panel of monoclonal antibodies directed against sAC. All other author(s) declare no competing financial interests.